Biochemical Potency: IC50, Ki And Selectivity
- Enzyme activity and binding screens with full concentration-response, not single points
- Counter-screens against related targets, so potency comes with its selectivity story
Services
Platforms
Solutions
About Us
Resources
De-Risk Your Screening Campaign, Hit to Lead.
Brief PhDs on your target, library and timeline.- Biochemical And Cell-Based Screens With Stated Controls And Acceptance Criteria
- IC50 And Concentration-Response Confirmation For Model-Nominated Compound Series
- Compound Exposure Verified By LC-MS/MS, So No Screen Result Is Ever A Mystery Dose
- Machine-Readable Results At Design-Cycle Cadence, Batch By Batch, With No Minimum
Regulated And Inspected By:
What The Screening Engagement Covers
The design-make-test-analyze loop turns only as fast as its slowest link, which for most AI-first teams is testing. We supply that part, with pharma-grade discipline in formats your model can read.
Hit Confirmation In Orthogonal Assay Formats
- Biochemical hits rechecked in cells, binding rechecked functionally before you commit
- Artifact chasing is cheaper at this bench than after three design cycles trusted a ghost
Cell-Based Activity And Cytotoxicity Screens
- Viability, cytotoxicity, proliferation and reporter readouts on endpoint-based formats
- Plate controls and pass criteria stated up front, so ranked hits stay ranked on rerun
Machine-Readable Data Built For Model Retraining
- Structured exports with plate maps, curve fits, QC flags and the format your team names
- Results feed back into the model without a human retyping numbers out of a PDF report
Exposure Checked By LC-MS/MS, Every Time It Matters
- Compound concentration verified in assay media and lysates on twelve LC-MS systems
- Solubility crashes and sticky compounds get caught here instead of haunting your SAR
The Upgrade Path When A Series Becomes A Program
- Winners route into ADME, PK and method development without changing labs or restarting
- The assay that picked your lead is documented to follow it toward IND-enabling work
What Makes Screening Data Model-Ready
Your pipeline needs controls that make plate forty comparable to plate one, orthogonal checks, exposure behind odd results and returns it can ingest.
-
Comparable Plates
Controls and normalization that make plate 40 comparable to plate 1
-
Orthogonal Checks
Actives confirmed by a second format before an artifact trains anything
-
Exposure Behind Odd Results
LC-MS verifies what the cells actually saw before a false negative is believed
LC-MS/MS -
Concentration-Response Rigor
Full curves on actives, never single-point verdicts
-
Structured Returns
Model-ready files with consistent fields, no PDF archaeology
-
Cadence The Loop Can Feel
Batches priced and run at research-tier speed, so design cycles keep moving
Non-GLP Testing
Ready To Start? Scope Your Screening Campaign.
Tailored screening quote in 2 days.
Your Models Move In Days, So Your Wet Lab Should Not Take Quarters
Screens fail on cost per compound and cycle time. We fix both by scoping to the decision, rank order now, depth later, where it is earned.
Talk Science First? Ask Our Screening Experts.
Discuss target, library and cascade.- Batches run as they exist with no minimum, and a standing assay turns repeat batches around inside a design cycle, so the loop keeps the cadence your computational team was hired for.
- We do not sell AI and never will: the offer is validated numbers with stated acceptance criteria, from the same instruments and scientists that run this lab’s regulated studies.
- When a series becomes a program, the same building carries it through ADME, PK, method work and GLP, so the assay that picked your lead follows it instead of dying in a handover.
2-4Weeks From Signature To First Screening Data Back
200+Investigational Drugs Supported Across Two Decades
What Does Discovery Screening Cost?
Research-tier pricing, per assay and per sample, with no minimum batch size: a three-compound pilot costs what a three-compound pilot should. Standing assays make repeat batches cheaper and faster than the first, and a senior scientist replies within two business days.
No Project Is Too Small To Start
Pilot batches and single-series questions are welcome; they are how discovery relationships begin here. When a series turns into a program, the pricing conversation grows with it instead of starting over.
Discovery Teams On Working With Our Lab
About 70% of our work comes from emerging biotech, and two thirds of the 100+ sponsors we work with each year return.
-
Co-Founder, Biotech & University PI
NorthEast BioLab tremendously supported us in reproducing our critical lab discoveries for drug metabolism
-
President & CSO, Biotech
We found their integrity as refreshing as readiness to provide creative scientific input and high-quality data
-
Executive Director, Pharmacokinetics
We trust NorthEast BioLab to design and execute streamlined, impactful bioanalytical projects
-
Sr. Dir., Bioanalytical Development & QC
NorthEast BioLab offers a science-based, hands-on approach to the latest bioanalytical platforms
-
VP, Development Operations
NorthEast BioLab’s scientists deliver high-quality data on time and within budget
-
VP, Biomarker Development
NorthEast BioLab is a responsive, collaborative, and reliable partner
Need a Screening Cascade? Primary to Confirmatory.
Share the target and library size. We'll design it.Why Do AI-First Teams Put Their Loop Through Our Lab?
We offer no robots for rent and no library for sale, only decision-grade numbers at the cadence your pipeline runs.
What You Receive
- Ranked actives with full concentration-response curves and stated acceptance criteria
- Structured, machine-readable exports: plate maps, curve fits, QC flags, your format
- Exposure verification by LC-MS/MS behind any result that looks too strange to trust
- A documented assay that follows the winning series into ADME, PK and method work
What We Need From You
- The target and the biology, with whatever assay history or literature already exists
- Compounds as solids or solutions, coded or blinded is fine, with handling constraints
- The decision each batch feeds, because that is what sets rigor, tier and turnaround
- Your data format of choice, so results land in the pipeline instead of in an inbox
Assay Development: A Comprehensive Guide to Types, Processes, and Applications in Drug Discovery
Drug discovery and development requires extensive testing, and assays are indispensable. Before we explore how assays are used, let us understand what is an assay, the meaning of assay in biology, and the assay definition in a pharmaceutical context….
One Model-Nominated Kinase Series Through The Loop: A Representative Cycle, Step By Step
The compounds land with the target and the ask, and ranked, comparable numbers come back with plate-to-plate controls intact. They go straight to training with no cleanup pass.
-
1. Kinase Series Nominated
Your model ranks a kinase inhibitor series; the list lands here with the target and the ask
-
2. Assay Standing By
Kinase assay qualified, Km ATP established, plate controls ready before the compounds land
-
3. Screen Batch Runs
Endpoint reads with plate controls, actives flagged against stated criteria
-
4. Concentration-Response
IC50 curves on the actives, with orthogonal checks before an artifact trains the model
-
5. Exposure Read
LC-MS/MS verifies what the cells actually saw behind every odd result
-
6. Model Retrained
Structured, model-ready files return; the next nominations are already smarter
Why Do Discovery Leads Choose Our Lab For Screening?
Because the answer returns while it can still change the next synthesis round, at screening cost, on methods that expand when a winner emerges.
Get Your Screening Cascade Reviewed By PhD Scientists.
Send your plan. We'll flag pitfalls before they cost you.- Loop cadence for real: batches as they exist and repeat batches inside your design cycle
- Pharma-grade discipline at the research tier, with acceptance criteria stated up front
- Twelve LC-MS systems, immunoassay, flow and PCR fleets behind every screening question
- One building from first screen to GLP, so winning series never restart at a new lab
Regulated And Inspected By:
Send The Target And Compound List For Numbers Your Model Can Ingest
Name the decision the batch feeds and the format your pipeline expects. The assay plan and quote come back on the platforms linked below.
Related FAQs
What discovery leads ask before committing a series, answered.
Do you run high-throughput screening?
Can you keep pace with weekly design cycles?
What format does the data come back in?
Do you screen blinded or coded compounds?
Do you run in vivo screening?
What happens when a series graduates?
Which screen types are available?
Explore More Solutions
Compounds that win the screen need ADME, PK and potency work next, all of which we run.
